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Abstract
Epidemiological and biological evidence support the association between heavy cannabis use and psychosis.
However, it is unclear which cannabis users are susceptible to its psychotogenic effect. Therefore, understanding
genetic factors contributing to this relationship might prove an important strategy to identify the mechanisms
underlying cannabis-associated psychotic experiences. We aimed to determine how variation in AKT1, COMT and
FAAH genotypes, and their interaction with three different groups (first episode psychosis (FEP) patients (n= 143),
controls (n= 92) and young adult (YA) cannabis users n= 485)) influenced cannabis experiences, in those who had
used cannabis at least once. We investigated the role of AKT1 (rs2494732), COMT Val158Met (rs4680) and FAAH
(rs324420) on cannabis experiences by combining data from a large case-control study of FEP patients, with a
naturalistic study of YA cannabis users (n= 720). Outcome measures were cannabis-induced psychotic-like
experiences (cPLEs) and euphoric experiences (cEEs). We used linear mixed effects models to assess the effects of
each genotype and their interaction with group, adjusting for age, sex, ethnicity, age of first cannabis use, years of
use and frequency. cPLEs were more frequent in FEP patients than controls and YA cannabis users. cEEs were more
prevalent in YA cannabis users than FEP patients or controls. Variation in AKT1, COMT or FAAH was not associated
with cPLEs/cEEs. There was no interaction between genotype and group (FEP cases, controls and YA cannabis users)
on cPLEs/cEEs. In conclusion, AKT1, COMT or FAAH did not modulate specific psychotomimetic response to
cannabis and did not interact with group, contrary to previous research.
Introduction
The use of cannabis has been associated with a 3.9-fold
increase in the risk of schizophrenia and other
psychosis-related outcomes among the heaviest cannabis
users compared to the nonusers1–3, but only a small
minority who use the drug will develop psychotic
symptomology. Although there is a debate about caus-
ality in the relationship between cannabis and psy-
chosis4,5, there is now new evidence that show that daily
use of high potency cannabis types contributes to rates
of psychotic disorders. In cities like Amsterdam and
London, 50% and 30% of new cases of psychotic dis-
orders can be attributed to the use of high potency
cannabis, respectively6. Indeed several studies have
shown that cannabis does produce transient psychoto-
mimetic effects, which are common and experienced by
nonclinical populations7. The term psychotomimetic
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implies mimicry of a wide range of experiences observed
in the psychosis continuum; and these may include
paranoia, hallucinations or euphoria8. These cannabis-
induced experiences may be a marker of a vulnerability
to psychosis, with those being most vulnerable, experi-
encing the greatest psychotomimetic effects9–12. How-
ever, there is marked interindividual variability in this
cannabis response. As well as environmental factors
such as pattern of cannabis use, genetic factors are
thought to play a key role in the differences in cannabis
sensitivity to the drug’s psychotomimetic effects.
Genetic differences in the dopaminergic system may
interact with cannabis use to increase the risk for the
development of psychosis13,14. Some evidence suggests
that delta-9-tetrahydrocannabinol (THC), the primary
psychoactive component in cannabis, acutely increases
dopamine release in the human striatum15–18, but studies
have been small and inconsistent19. The catechol-o-
methyltransferase (COMT) gene encodes an enzyme
that breaks down catecholamines such as dopamine.
COMT is specifically important for the dopaminergic
tone in the prefrontal cortex. The COMT rs4680 G/A
polymorphism causes a non-synonymous change from a
valine (Val) amino acid to a methionine (Met) amino acid.
This amino-acid change leads to a three-to-fourfold
reduction in COMT activity, and therefore greater levels
of dopamine in the prefrontal cortex20,21. Caspi et al.13
found a gene × environment interaction between allelic
variation in COMT and cannabis use on the development
of schizophrenia wherein Val alleles were identified as the
risk allele for psychosis (n= 953)13. It follows that those
with the risk allele (Val) would show greater psychoto-
mimetic effects in response to cannabis as found by
Henquet et al.22–25. However, subsequent findings have
been shown to be inconsistent and rs4680 has not been
identified as a causal variant in the latest schizophrenia
Genome Wide Association Studies (GWAS)26–30. One
recent review suggests this inconsistency may be a result
of study design in that the interaction was only significant
in case-only studies but not in studies that used other
clinical outcomes/nonclinical psychosis and that future
studies should utilise additional control groups31.
The Protein Kinase B family, which consists of three
serine/threonine kinases (AKT1, 2 and 3), is another
integral component of dopaminergic signalling. It acts
downstream of the dopamine D2 receptor. The AKT1
gene has been associated with schizophrenia in several
independent samples32–34, although these findings are
not consistently replicated35,36. A replicable gene ×
environment interaction in which the minor C allele of
the rs2494732 SNP has been associated with an increased
likelihood of developing a psychotic disorder in those
with a history of cannabis use (n= 489-801 patients and
278–704 controls/unaffected siblings, respectively)37,38.
Among daily users, this increased seven-fold for C car-
riers in comparison to TT carriers37. Recent research
suggests that genetic variation in AKT1 is involved in the
cognitive effects of cannabis on psychosis (ref. 39 n= 611)
and on the acute psychotomimetic effects of smoked
cannabis (ref. 29 n= 442) as assessed by the Psychoto-
mimetic States Inventory (PSI; ref. 8). However, the
functional consequences of this intronic SNP are unclear,
and so far, it has not been associated with any protein
change. However, data from HapMap 340 has shown that
rs2494732 is 702 base-pairs away from rs1130233, a SNP
which does affect AKT gene messenger RNA expres-
sion41. Rs2494732 and rs1130233 are therefore most
likely in linkage disequilibrium (r2= .95), and this may
explain the convergent evidence of research investigating
the AKT1-cannabis interaction on both psychosis out-
comes38,42 and altered cognitive performance39 when
investigating both SNPs37. However, it should be noted
that rs2494732 has not yet been identified in GWAS as a
causal variant30.
Since cannabis primarily acts on the endocannabinoid
(eCB) system, it seems pertinent to also investigate
interactions within this system. The eCB system is a sig-
nalling system made up of receptors (CB1, CB2), internal
ligands (anandamide and 2-AG: 2-Arachidonoylglycerol),
and enzymes (Fatty Acid Amide Hydrolase (FAAH) and
Monoacylglycerol lipase (MAGL)), which are responsible
for degradation and reuptake of eCBs. The “cannabinoid”
hypothesis of schizophrenia hypothesises that eCB over-
activity may contribute to the pathophysiology of schi-
zophrenia. Recently, meta-analysis has shown that the
eCB system may be dysregulated in patients at all stages of
the psychosis continuum, in comparison to controls43.
Patients have higher levels of anandamide in their cere-
brospinal fluid, blood and greater CB1 receptor expres-
sion on peripheral immune cells43. Bioque et al.44 found
that first episode psychosis (FEP) patients (n= 95) in
comparison to healthy controls (n= 90) had a dysregu-
lated eCB system where they not only showed increases in
the synthesising enzymes but also significant decreases in
the degrading enzymes. This effect was exaggerated in
FEP patients who used cannabis44. Anandamide levels
were also found to be downregulated in heavy cannabis
users without a psychotic disorder45 and the extent of this
anandamide change was associated with a lower risk of
psychotic symptoms when drug free (n= 20)45. Addi-
tionally, in a clinical trial with individual’s diagnosed with
schizophrenia, cannabidiol (CBD), the non-intoxicating
cannabinoid in cannabis, and potential FAAH inhibitor,
increased plasma levels of anandamide and this correlated
with clinical improvement (n= 39)46. It was therefore
hypothesised that one of the mechanisms of clinical
improvement was through inhibition of the FAAH
enzyme46.
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The FAAH rs324420 C to A polymorphism leads to a
non-synonymous exchange from proline to threonine at
amino acid 129 of the protein. Those who are homo-
zygous for the A allele have a 30% reduction in the
functioning of the enzyme47–49. The A allele can there-
fore act as a human genetic model of FAAH inhibition
associated with increased anandamide levels, and has
been shown to protective against anxiety, stress and fear-
related behaviour50,51. Therefore, on the one hand,
anandamide is reliably increased in psychotic patients43
and on the other, the gene associated with inhibition of
FAAH, that breaks down anandamide, may be protective
against anxiety. The FAAH genotype has not been
investigated in relation to cannabis-induced psychotic-
like effects before. However, it has been investigated in
its association with population-level schizophrenia (n=
260) where no relationship was found52. Moreover, the
FAAH rs324420 SNP has also not been associated with
diagnosis in the latest schizophrenia GWAS30. Post-
mortem studies have also reported that enzymes that
regulate endocannabinoid levels do not differ between
schizophrenia and age- and sex-matched comparison
participants53. Therefore, how the FAAH genotype and
anandamide play a role in psychosis is still being
debated.
In this study, we combine data from two large-scale
studies. The GAP study is a case-control study based in
South London54. The second is a naturalistic study of
young adult (YA) cannabis users conducted in the UK55.
Sections of this data have previously been published. Di
Forti et al.37 analysed AKT1 in relation to risk of psy-
chosis in cannabis users in the FEP sample. The AKT1
and COMT genotype data were analysed in relation to
acute psychotomimetic effects in Morgan et al.29 in the
YA study. However, for this first time, in this secondary
analysis we assess participants who used cannabis who
were administered a modified cannabis experiences
questionnaire (CEQ), that was a priori coordinated
across the two studies and here we look at the con-
tribution of the three SNPs: AKT1 COMT and FAAH,
which have not previously been analysed together in
either sample. The aim of coordinating over studies was
to increase the sample size, as previous candidate gene
studies have been limited by their small sample sizes. We
aimed to investigate between group differences (controls,
YA cannabis population, and FEP patients). We hypo-
thesised interactions between genotype and group
wherein the risk allele for psychosis for each SNP will
show the greatest effect on cannabis-induced psychotic-
like experiences in the psychosis population, in com-
parison to both the case-matched controls and the YA
cannabis users. For the first time, we investigate the
relationship between genetic variation in the FAAH gene
and its relationship to cannabis-induced experiences.
Materials and methods
Study participants
GAP study
This study utilized a subsample of the Genetic and
Psychosis (GAP) study56. The GAP study recruited 410
patients with FEP and 370 population control partici-
pants, referred to as “GAP controls”56. This case-control
study approached all FEP patients aged 18–64 in the
Lambeth, Southwark, Croydon adult inpatient units of the
South London and the Maudsley NHS trust between Dec
2005 and Oct 2010. Controls were matched on education
and employment status but not cannabis use. Inclusion
criteria for cases were: 18–65 years/old presenting to
psychiatric services for the first time with a psychotic
disorder (codes F20–29 and F30–33 from the Interna-
tional Classification of Diseases [ICD-10]), and resident
within tightly defined catchment areas in Southeast
London, UK. Exclusion criteria were: organic psychosis;
intelligence quotient (IQ) under 70; previous contact with
services for psychosis, and transient psychotic symptoms
resulting from acute drug intoxication. Further details can
be found in refs. 37,56. Controls were aged 18–65 years and
recruited from the population locally living in the above
areas and were recruited via internet and newspaper
advertisements, and leaflet distribution within the local
area. The Psychosis Screening Questionnaire (PSQ) was
administered to all potential control group participants;
individuals were excluded if they met criteria for a psy-
chotic disorder. Participants for this analysis were inclu-
ded if they had completed the CEQ and therefore had
used cannabis at least once, and had data available on the
three SNPs, therefore the number of cases and controls
from the GAP study that are analysed vary. All partici-
pants provided written, informed consent. Ethical
approval was provided by the South London and
Maudsley and Institute of Psychiatry Local Research
Ethics Committee.
YA cannabis user study
The second sample was a naturalistic study of 16–24-
year-old cannabis users who did not have any diagnosed
psychiatric health problems (n= 611)29,55,57. In order to
represent a wide range of cannabis exposure, recruitment
was targeted at both recreational (1–24 days/month) and
daily (≥25 days/month) users. Participants were identified
through word of mouth and snowball sampling, starting
with undergraduate students and the local community
around UCL (Central London) between November 2008
and January 2011. Participants completed the CEQ and
provided saliva samples for DNA when non-intoxicated.
All participants provided written, informed consent. The
study was approved by the UCL Ethics Committee and its
aims were supported by the UK Home Office. To be
included in the study, participants were required to speak
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English fluently, have no learning disability, no personal
or first degree relative history of psychotic illness and have
normal or corrected to-normal vision.
2.2 Assessments
Cannabis experiences questionnaire (CEQ)
Modified from Barkus et al.10 and utilised in Di Forti
et al.56, this questionnaire assesses the lifetime frequency
of nine intoxication experiences, six are psychotic-like
experiences (cPLE; feeling fearful; feeling crazy or mad;
feeling nervy; feeling suspicious; hearing voices; seeing
visions), and three are euphoric experiences (cEE; feeling
happy; understanding the world better; being full of plans
or ideas). They were rated on a 5 point Likert scale: (0
rarely or never, 1 from time to time, 2 sometimes, 3 more
often than not, 4 almost always). Factor analysis of the
CEQ suggests that individual items load onto two scales—
cPLE and cEE58 and these were used as our two outcome
variables.
Demographics and cannabis use
In both studies, whilst non-intoxicated, participants
provided demographic details including Age, Sex (male/
female) and Ethnicity (White British, White Other, Mixed,
Indian, Pakistani, Bangladeshi, Other Asian, black Car-
ibbean, Black African, Black other, Chinese, Other).
Cannabis use history variables included age of first can-
nabis use (years), number of years of cannabis use and
frequency of cannabis use (categories: everyday; more
than once a week; a few times a month; a few times each
year; only once or twice).
Genotyping
In both studies, DNA extraction was performed using
standard phenol–chloroform methods for all samples. Off
the shelf Taqman assays for these polymorphisms are
available as a kit (Applied Biosystems, Life Technologies,
Paisley, UK https://www.thermofisher.com/uk/en/home/
brands/applied-biosystems.html). In the GAP study, 75%
samples were blood and 25% were cheek swabs37. A
comparison of genotype results for 360 individuals with
overlapping blood and cheek swab DNA revealed there
was 100% concordance between blood- and cheek-derived
genotype data. In the cannabis user study, 100% of DNA
was obtained by cheek swabs.
As the purpose of this study was to explicitly test for an
interaction at three SNPs, we focused on AKT1:
(rs2494732), COMT: Val158Met (rs4680), and FAAH
(rs324420). Genotype calls were discriminated based on
algorithmic membership of three clusters representing
TT/CT/CC genotype classes for AKT1 rs2494732. AA/
AG/GG genotype classes for COMT rs4680, and CC/AC/
AA genotype classes for FAAH rs324420. The
nomenclature was based on previous research29,31,59. In
order to increase the power to detect an interaction, for
AKT1, those with the minor allele CC were combined
with heterozygotes CT. For COMT, GG and AG were
combined and for FAAH, the minor allele A was com-
bined with the heterozygote AC.
Statistical analysis
Statistical analysis was conducted using SPSS version
24; IBM, Chicago, IL, USA and Stata/IC v. 15.1 (Stata-
Corp, College Station, TX). The code is available from the
corresponding author at request. An a priori power cal-
culation conducted with G*Power to calculate the sample
size required to achieve a study power of 80% at a 5%
significance level and effect size of f= 0.1 suggested 81
participants were required; with 10 predictors. A small
effect size was chosen in line with previous behavioural
genetics research.
Participants were included in the statistical analysis if
they had used cannabis at least once, completed the CEQ
and had genetic data available. We calculated cPLEs and
cEEs by simple summation as per Sami et al.60,61. There
were half as many euphoric items as psychotic-like items,
so scores for euphoric items were doubled. Where a single
item was missing, we imputed the mean of the subscale
into the item, and recalculated the subscale. This was the
case for seven participant’s cPLE scores and four partici-
pant’s cEE scores. If more than one item was missing for
the subscale and precluded the calculation of a subscale,
this was considered missing data (1.25% of data).
We compared the three groups on demographics, can-
nabis use variables and genotypes using Chi-squared tests
and one-way analysis of variance (ANOVA). Extreme
values >3x Standard Deviation were winsorized to the
next highest value +1 SD (non-outlier). This was the case
for <1% of the continuous data. When homogeneity of
variance could not be assumed, we conducted a Brown
Forsythe test. Pairwise comparisons were Bonferroni
corrected.
We conducted linear mixed effects models (LMMs)
regressing the genotypes, group and their interaction
onto the two outcome variables (cPLE and cEE) in
individual models. Only full cases were analysed. In every
model, we co-varied for the other subscale of the CEQ
following Sami et al.60,61, and because there was a small
but significant correlation between cPLEs and cEEs
(r(719)=0.13, p= 0.001). Sex was coded as 0 (male) or 1
(female), with males being the reference category. Self-
reported ethnicity was coded by category. The YA can-
nabis user study did not have ethnicity derived from
genetic data. To confirm self-report of ethnicity in the
GAP sample, genetic ancestry was derived using a panel
of 57 ancestry informative genetic markers37. These were
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Table 1 Group data for demographics, cannabis use data and genetics.
Whole sample
(n= 720)
FEP patients (GAP)
(n= 143)
GAP controls
(n= 92)
YA cannabis
users (485)
Test statistic
Age at testing (M(SD)) 23.5 (6.6) 28.4 (8.36) 30.1 (9.5) 20.7 (1.8) F(2,204.6)= 82.2,
p ≤ 0.001, ɳ2= 0.36a
Gender (N) M: 489
F: 231
M: 97
F: 46
M: 52
F: 40
M: 340
F: 145
χ2(2)= 6.5, p= 0.038,
V= 0.10
Ethnicity (N) χ2(22)= 158.424,
p ≤ 0.001, V= 0.30
White British 359 49 44 266
White Other 85 16 17 52
Mixed 45 14 4 27
Indian 38 0 2 36
Pakistani 8 0 1 7
Bangladeshi 5 4 0 1
Other Asian 48 5 2 41
Black Caribbean 50 26 15 9
Black African 36 20 6 10
Black other 3 3 0 0
Chinese 17 1 0 16
Other 25 5 1 19
Age of first cannabis use (M(SD)) 15.3 (3.0) 16.3 (5.0) 16.3 (3.0) 14.9 (2.0) F(2,166.53)= 10.04,
p ≤ 0.001, ɳ2= 0.04a
Years of cannabis use (M(SD)) 6.34 (5.3) 10.06 9.95 (8.9) 4.8 (2.5) F(2,155)= 31.8, p ≤ 0.001,
ɳ2= 0.19a
AKT1 (N) 635 102 70 436 χ2(4)= 2.27, p > 0.05,
V= 0.04
TT 160 (25.2%) 22 (21.6%) 17 (24.3%) 121 (26.1%)
CT 326 (51.3%) 54 (52.9%) 40 (57.1%) 232 (50.1%)
CC 149 (23.5%) 26 (25.5%) 13 (18.6%) 110 (23.8%)
HW stat χ2= 1.17, p > 0.05 χ2= 0.37, p > 0.05 χ2= 1.5, p > 0.05 χ2= 0.0
p > 0.05
COMT (N) 657 113 91 453 χ2(4)= 16.93, p= 0.002,
V= 0.11
AA 143 (21.8%) 11 (9.7%) 15 (16.5%) 117 (25.8%)
AG 316 (48.1%) 58 (51.3%) 46 (50.5%) 212 (46.8%)
GG 198 (30.1%) 44 (38.9%) 30 (33%) 124 (27.4%)
HW stat χ2= 0.64 p > 0.05 χ2= 0.9, p > 0.05 χ2= 0.14, p > 0.05 χ2= 1.8, p > 0.05
FAAH (N) 654 115 84 455 χ2(4)= 12.24, p= 0.016,
V= 0.10
CC 409 (62.5%) 71 (61.7%) 42 (50%) 296 (65.1%)
AC 206 (31.5%) 39 (33.9%) 21 (36.9%) 136 (29.9%)
AA 39 (6.0%) 5 (4.3%) 11 (13.1%) 23 (5.1%)
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genotyped using iPLEX technology developed for the
MassArray platform (Sequenom Inc., San Diego, Cali-
fornia). Eighty-three percent of participants had infor-
mation on both self-reported ethnicity and ancestry
markers in the GAP study. The level of overall agree-
ment between self-reported and genetic ethnicities (96%)
was reassuringly high in the GAP study. In this analysis,
we correlated the genetic and self-reported ethnicity in
the GAP study, which showed a strong correlation (R
(32)=0.7, p < 0.01); so we utilised self-reported ethnicity
for both studies. Frequency of cannabis use was coded
from 0–4, with “everyday” being the reference category
such that a negative beta means greater frequency of
cannabis use associated with the cannabis-induced
experience. Group was coded to infer increasing risk
of psychosis with 0= controls from the GAP study, 1=
YA cannabis users and 2= FEP patients from the GAP
study. AKT1 was coded as 0 (TT) or 1 (CC or CT).
COMT was coded as (0- AA i.e. MET/MET) or 1 (GG or
AG i.e. VAL/VAL or VAL/MET). FAAH was coded as 0
(CC) or 1 (AA or AC). The gene × group interaction was
therefore calculated as SNP (0, 1) × group (0, 1, 2), with
the reference categories being GAP controls with the
lowest genetic risk. The final LMMs were checked for
violation of assumptions. All final models include a
random intercept for ‘participant’ to account for addi-
tional residual variability. Unadjusted associations from
linear regression between each variable with cPLEs and
cEEs can be found in Supplementary materials 1. The
unstructured variance-covariance structure was selec-
ted. Multicolinearity was not an issue (all VIFs >1 & <5).
All P values were thresholded at P < .05 (FDR-corrected
for multiple comparisons). All main effects and inter-
actions were compared against this alpha. Finally, given
differences in ethnic groups across allele frequencies, we
conducted sensitivity analyses without black individuals
(supplementary materials Tables 1–3 sensitivity analysis
1) and also within just the major ethnicity group i.e.
white European (supplementary materials Table 4–6
sensitivity analysis 2).
Results
Demographics and cannabis use variables
Data were available for a total of 720 participants all of
whom had used cannabis at least once and completed the
CEQ (Table 1). As per Table 1, groups varied significantly
on demographic and drug use variables. YA cannabis
users were younger than FEP patients (p < 0.001) and
GAP controls (p < 0.001). No difference in age emerged
between FEP patients and GAP controls (p= 0.056). The
GAP controls had a more even distribution of males to
females than the FEP patients and the YA cannabis users
(χ2(2)= 6.5 p= 0.038). The YA cannabis users had more
white British individuals and the GAP study (FEP and
controls) had more black Caribbean, African and black
other participants, likely due to differences in sampling
strategy. In regards to cannabis use, the YA cannabis users
started at an earlier age than the FEP patients (p < 0.001)
and GAP controls (p < 0.001). No difference emerged
between FEP patients and GAP controls in the GAP study
(p= 1.00). YA cannabis users had smoked cannabis for
less years than FEP patients (p < 0.001) and GAP controls
(p < 0.001). Cannabis frequency significantly differed
between groups (χ2(10)= 99.1, p ≤ 0.001). FEP patients
had relatively more individuals using cannabis everyday
followed by the YA cannabis users and the GAP controls
(Supplementary Fig. 1). There was a similar number of
daily and ‘more than weekly’ users in the YA cannabis
users, and there were more GAP controls who used
cannabis ‘more than once a week’ in comparison to FEP
patients (Supplementary Fig. 1).
Group differences in cannabis experiences
Score on cPLEs and cEEs, are shown in Fig. 1 and Table
1. There were significant differences between the three
groups on cPLEs (F(2,708)= 10.85, p < 0.001). There was
little difference between the GAP controls and the YA
cannabis users but both differed significantly from the
FEP patients who experienced greater cPLEs (p’s ≤ 0.002).
In regards to cEEs, there were significant differences
between the three groups (F(2,716)= 14.99, p < 0.001).
The YA cannabis users experienced greater cEEs than
Table 1 continued
Whole sample
(n= 720)
FEP patients (GAP)
(n= 143)
GAP controls
(n= 92)
YA cannabis
users (485)
Test statistic
Cannabis-induced –Psychotic-
Like experiences (M(SD))
9.26 (3.68) 10.54 (4.74) 8.90 (3.16) 9.00 (3.33) F(2,288.58)= 9.43,
p ≤ 0.001, ɳ2= 0.02a
Cannabis- induced Euphoric
Experiences (M(SD))
17.86 (5.97) 16.91 (7.20) 15.28 (5.96) M= 18.6 (5.38) F(2, 293.85)= 12.57
p < 0.001, ɳ2= 0.04a
HW Hardy Weinberg, ɳ2 eta squared, V Cramer’s V.
aBrown-Forsyth Test.
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GAP controls (p < 0.001) and FEP patients (p= 0.006).
There was no difference between the FEP patients and the
GAP controls (p= 0.11). Given that YA cannabis users
were younger than both FEP patients and GAP controls
and therefore had less years of cannabis use, the effects on
cPLEs and cEEs may be a function of age. Therefore as an
additional check, we restricted the analysis to those who
were between 16–24 years old and replicated the group
differences.
Genotypic frequencies
Across all participants, genotypes were in Hardy
Weinberg Equilibrium (HWE). HWE was violated for the
distribution of FAAH in GAP control sample only; how-
ever, this did not modify the overall HWE for FAAH
(Table 1).
Linear mixed effects models
AKT1
In the model predicting cPLEs, there was a positive
association between cEEs and cPLEs (B:0.09, 95% CI:0.04
to 0.14) (Table 2). There was negative association with age
such that younger individuals had greater cPLEs (B:
−0.13, 95% CI:−0.25 to −0.02) but this result did not
survive an FDR < 0.05. FEP patients, in comparison to
GAP controls, showed greater cPLEs (B: 3.74, 95% CI:
1.37 to 6.12) as part of the main effect of group (χ2(2)=
10.56, p= 0.005). There was no main effect of AKT1.
There was no overall interaction between AKT1 and
group (χ2(2)= 5.69, p= 0.06).
In regards to cEEs, there was a positive association with
cPLEs (B: 0.24, 95% CI: 0.12 to 0.37). This model also
showed a negative association with age suggesting
younger individuals were experiencing greater euphoric
effects of cannabis (B: −0.2 95% CI:−0.39 to −0.02).
There was a positive association with years of cannabis
use (B: 0.28, 95% CI: 0.1 to 0.46) wherein those individuals
with more years of cannabis use had experiencing greater
cEEs. There was no main effect of AKT1 or group or
interaction between AKT1 and group on cEEs.
COMT
In the model predicting cPLEs, apart from a positive
association of cEEs with cPLEs (B: 0.1, 95% CI: 0.05 to
0.15), there were no other associations (Table 3). In
regards to cEEs, there was a positive association with
cPLEs (B: 0.24, 95% CI: 0.12 to 0.37). There was also a
negative association with frequency of cannabis use, such
that greater cannabis use was related to greater cEEs (B:
−0.43, 95%CI: −0.85 to −0.02), and a positive association
with years of cannabis use such that those with greater
years experienced more cEEs (B: 0.17, 95% CI: 0.02 to
0.33).
FAAH
Similar to the above models, there was a positive asso-
ciation between cEEs and cPLEs (B: 0.08, 95%CI: 0.03 to
0.13) in the model predicting cPLEs (Table 4). We also
saw a negative association with age of first cannabis use,
such that those who started using cannabis earlier
reported greater cPLEs (B: −0.16, 95% CI: −0.29 to
−0.03). There was a main effect of group (χ2(2)= 31.46, p
< 0.001) as evidenced by lower cPLEs in the YA cannabis
users than GAP controls (B: −1.76, 95% CI: −3.25 to
−0.28; p= 0.02). There was no main effect of FAAH and
there was no interaction between group and FAAH. In
regards to the model predicting cEEs, there was a positive
association between cPLE and cEE (B: 0.24, 95% CI: 0.11
to 0.37). There was a significant positive association
between years of cannabis use and cEEs (B: 0.19, 95% CI:
0.04 to 0.35). There was no main effect of FAAH or group
or interaction with FAAH.
Sensitivity analysis
In the above analyses, we have controlled for the
confounding effects of ethnicity. However, for COMT
and FAAH there are population-wide differences
between the across the main (black and white Eur-
opeans) ethnic groups62, but this is not the case for
AKT137. Allele frequency by ethnicity reported as a
percentage of the total sample can be found in supple-
mentary table 7. Therefore, we replicated the above
analysis twice. Once without individuals whose self-
reported ethnicity was black African, black Caribbean
and black Other (supplementary materials Tables 1–3
sensitivity analysis 1) and once only in those who self-
reported being white European or white other
Fig. 1 Cannabis-induced expereinces by group. Mean (±SEM)
scores for cannabis-induced psychotic-like experiences (cPLE) and
euphoric experiences (cEE) based on group (FEP patients, GAP
controls and YA cannabis users). Bonferroni corrected pairwise
comparisons are shown. Overall psychotic cases experienced most
psychotic symptoms but cannabis users experienced most euphoric
symptoms. ***p < 0.001, **p < 0.01 *p < 0.05.
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(supplementary materials Table 4–6 sensitivity analysis
2). The findings can be seen in the supplementary
materials. In short, the results remain very similar to the
main analysis reported above but with less power due to
decreases in sample size.
Discussion
In this study, as hypothesised, we found that FEP
patients experienced greater cPLEs than GAP controls
and YA cannabis users, but YA cannabis users experi-
enced the greatest cEEs, followed by FEP patients then
GAP controls. This study did not find any association
between the Val158Met polymorphism of the COMT
gene with cPLEs or cEEs whilst accounting for demo-
graphics and cannabis use variables. Our findings add to
the existing mixed findings that the meta-analysis by
Vaessen et al.31, suggested are likely due to differences in
study design regarding the control group. Our study, is
the first to include two independent control groups, which
reduces the likelihood of over-estimating the true effect
which case-only studies do.
Our findings regarding AKT1 contrast with three pre-
viously published studies. In Morgan et al.29 the acute
change in the psychotomimetic effect of smoked cannabis
was modulated by the AKT1 genotype wherein the C
allele was associated with greater intoxicated psychoto-
mimetic symptoms. COMT had no effect. Di Forti et al.37,
replicated the Van Winkel et al.39 case-control data,
showing that CC genotype carriers of AKT1 with a history
of cannabis use showed a two-fold increase in the ORs for
a psychotic disorder, in comparison to TT carriers and an
interaction with the genotype and frequency of use was
found on case/control status. They found that among
daily users, C carriers had a seven-fold increase in the
odds of psychosis diagnosis.
A key difference between this study and Morgan
et al.29 is the measure of cPLE. We used the CEQ, a
retrospective measure of nine items in comparison to
Morgan et al.29 who used the PSI (under acute cannabis
exposure), which has better test-retest reliability than
other scales designed to tap psychotic-like effects63.
Further, Di Forti et al.37 and van Winkel et al.39 did not
Table 2 Adjusted mixed effect model predicting cannabis-induced psychotic-like experiences (cPLE) and euphoric
experiences (CEE) from covariates, AKT1 genotype and the interaction between AKT1 and group (GAP controls (n= 48);
YA cannabis users (n= 442) and patients (n= 87)). Each model contains a random effects parameter of “participant”.
cPLEs cEEs
B 95% CI p B 95% CI p
cEE 0.09 0.04 to 0.14 0.003 – – –
cPLE – – – 0.24 0.11 to 0.36 <0.001
Age −0.13 −0.25 to -0.02 0.02 −0.20 −0.39 to -0.02 0.03
Sex −0.36 −0.98 to 0.27 0.26 −0.53 −1.53 to 0.48 0.30
Ethnicity −0.00 −0.07 to 0.07 0.74 0.00 −0.10 to 0.12 0.92
Age of first cannabis use −0.12 −0.26 to 0.03 0.11 0.19 −0.04 to 0.43 0.10
Frequency of cannabis use −0.14 −0.42 to 0.12 0.29 −0.36 −0.79 to 0.08 0.11
Years of cannabis use 0.04 −0.08 to 0.15 0.54 0.28 0.10 to 0.46 0.003
Groupa
YA Cannabis users 1.71 −0.54 to 3.98 0.13 0.56 −3.05 to 4.17 0.76
FEP Patients 3.74 1.37 to 6.12 0.002 0.83 −3.02 to 4.66 0.67
AKT1 2.02 −0.13 to 4.18 0.066 0.41 −3.05 to 3.87 0.81
groupaAKT1b
YA cannabis users × AKT1 −2.29 -4.57 to -0.00 0.05 −0.32 −3.98 to −3.34 0.86
FEP Patients × AKT1 −3.33 −6.09 to −0.57 0.02 −0.54 −4.98 to 3.89 0.81
Constant 10.88 7.67 to 14.01 <0.001 16.28 11.11 to 21.44 <0.001
N 578 578
Wald χ2(12) 64.25 p < 0.001 36.62 p < 0.001
aReference category: GAP controls.
bReference category: GAP controls with AKT1 homozygote TT genotype; multiple comparisons are corrected with a FDR of 0.05. Results in bold are significant.
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measure cPLE but OR for case-control status, which was
diagnosed by a clinician.
Indeed, this is the first study to investigate the role of
the FAAH rs324420 genotype in relation to cPLEs.
Previous evidences have suggested a possible role of the
eCB system in psychosis. Patients suffering from all
stages of psychotic disorders have increased plasma and
cerebrospinal fluid levels of anandamide, independent of
antipsychotic treatment and current cannabis use43,64.
However, previous population-wide and postmortem
research on the FAAH rs324420 genotype, where the A
allele leads to the 30% reduction in the functioning of the
enzyme47–49 have not shown any associations with
schizophrenia52,53. We did not find evidence that the
FAAH rs324420 SNP was associated with either CEQ
measure. Future research with case/control status and
cannabis use is warranted based on research that sug-
gests anandamide is also downregulated in chronic
cannabis users45. We did not have evidence for the
functional consequences of FAAH or the other SNPs.
This is important because there may be neurobiological
variation related to having FEP or regular cannabis use,
which may modulate anandamide levels. Indeed, future
studies should aim to externally validate the con-
sequences of the SNPs examined. More work is needed
to investigate role of the eCB system in schizophrenia
and cannabis-induced experiences, as previous research
has shown that the FAAH rs324420 SNP is involved in
behavioural manifestations of cannabis addiction59. In
these times of changing cannabis legislation, research
highlighting the biological effects of cannabinoids is
greatly needed in the face of concerns about unintended
negative consequence of cannabis use.
The hypothesis that these specific genetic SNPs would
be involved in the acute cannabis experience was based on
previous research suggesting that these SNPs have a
causal effect on the biological systems associated with
development of psychosis. However, while genetic factors
appear to play a role in the relationship between cannabis
and psychosis, it is also clear that other environmental
Table 3 Adjusted mixed effect model predicting cannabis-induced psychotic-like experiences (cPLE) and euphoric
experiences (CEE) from covariates, COMT genotype and the interaction between COMT and group (GAP controls (n= 66);
YA cannabis users (n= 432) and patients (n= 94)). Each model contains a random effects parameter of “participant”.
cPLEs cEEs
B 95% CI p B 95% CI p
cEE 0.10 0.05 to 0.15 <0.001 – – –
cPLE – – – 0.24 0.12 to 0.37 <0.001
Age −0.10 −0.19 to 0.00 0.06 −0.14 −0.30 to 0.02 0.08
Sex −0.49 −1.10 to 0.13 0.13 −0.65 −1.64 to 0.35 0.20
Ethnicity −0.01 −0.08 to 0.06 0.72 0.04 −0.07 to 0.15 0.50
Age of first cannabis use −0.12 −0.26 to 0.01 0.07 0.09 −0.13 to 0.30 0.45
Frequency of cannabis use −0.18 −0.44 to 0.09 0.19 −0.43 −0.85 to -0.02 0.04
Years of cannabis use −0.01 −0.09 to 0.11 0.87 0.17 0.02 to 0.33 0.03
Groupa
YA Cannabis users −0.13 −2.80 to 2.55 0.93 −0.99 −5.27 to 3.27 0.65
FEP Patients 1.47 −1.66 to 4.87 0.34 4.37 −0.84 to 9.58 0.10
COMT −0.46 −2.90 to 1.98 0.71 −0.74 −4.65 to 3.16 0.70
groupaCOMTb
YA cannabis users × COMT 0.70 −1.85 to 3.24 0.59 1.00 −3.08 to 5.06 0.64
FEP Patients × COMT −0.14 −3.54 to 3.25 0.93 −4.62 −10.04 to 0.80 0.09
Constant 11.98 8.41 to 15.55 <0.001 18.52 12.81 to 24.24 <0.001
N 592 592
Wald χ2(12) 64.25 p < 0.001 46.10 p < 0.001
aReference category: GAP controls.
bReference category: GAP controls with homozygote COMT AA (MET/MET) genotype; multiple comparisons are corrected with a FDR of 0.05. Results in Bold are
significant.
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factors are critically important. In our statistical models,
we found that an increase in one subscale is highly
associated with an increase in the other subscale, sug-
gesting cPLEs and cEEs are highly correlated. Addition-
ally, we found differences between groups on cPLEs and
cEEs. We also see strong effects of cannabis use itself;
years of cannabis use predicted cEEs in both the AKT1
and FAAH models and age of first cannabis use predicted
cPLEs in the FAAH model. This pattern of results has
been found previously in both local12 and multinational
samples61. Moreover, an interesting pattern of results
emerges in the models in regards to age, years of cannabis
use and cEEs. In all cEE models, there were negative
associations with age, such that those who are younger,
experienced greater euphoric effects of cannabis. There
were positive associations with years of cannabis use,
suggesting the more years of cannabis use, the greater the
euphoric experiences. Overall, this may suggest that
younger, more experienced cannabis users, regardless of
group, may be most sensitive to the acute euphoric
experiences of cannabis such as feeling happy,
understanding the world better and being full of plans or
ideas. While genetic factors may play some mediating role
between cannabis and psychosis, the contribution of a
range of environmental factors, such as population den-
sity65 and childhood trauma66 and their interaction with
genotype is less understood.
Although in the present study we concentrated on three
SNPs that have been previously been highlighted in
research on the putative biological mechanisms associat-
ing cannabis and psychosis, data that arises from GWAS
should guide future research. The fact that the SNPs
investigated in this analysis have not been investigated
and replicated as causal variants in schizophrenia GWAS
limits the interpretation of these findings. Particularly, the
expression of the neuronal acetylcholine receptor alpha-2
subunit CHRNA2 was found to be significant in the
GWAS of cannabis use disorder67 and in the largest
schizophrenia GWAS68. Additionally there may be a
strong biological link between the expression of CHRNA2
and the gene that encodes the cannabinoid receptor type
1 (CNR1), which is based on the assessment of
Table 4 Adjusted mixed effect model predicting cannabis-induced psychotic-like experiences (cPLE) and euphoric
experiences (CEE) from covariates, FAAH genotype and the interaction between FAAH and group (GAP controls (n= 61);
YA cannabis users (n= 434) and patients (n= 95)). Each model contains a random effects parameter of “participant”.
cPLEs cEEs
B 95% CI p B 95% CI p
cEE 0.08 0.03 to 0.13 <0.001 – – –
cPLE – – – 0.24 0.11 to 0.37 <0.001
Age −0.07 −0.17 to 0.03 0.15 −0.14 −0.30 to 0.01 0.06
Sex −0.47 −1.08 to 0.15 0.14 −0.73 −1.71 to 0.29 0.13
Ethnicity −0.02 −0.09 to 0.05 0.60 0.03 −0.09 to 0.14 0.57
Age of first cannabis use −0.16 −0.29 to −0.03 0.02 0.14 −0.74 to 0.35 0.14
Frequency of cannabis use −0.04 −0.28 to 0.21 0.77 −0.53 −0.94 to −0.12 0.15
Years of cannabis use −0.00 −0.10 to 0.10 0.97 0.19 0.04 to 0.35 0.01
Groupa
YA Cannabis user −1.76 −3.25 to −0.28 0.02 0.52 −2.22 to 3.26 0.71
FEP Patients 0.69 −0.86 to 2.24 0.38 −0.48 −2.96 to 2.00 0.70
FAAH −0.70 −2.42 to 1.03 0.43 −0.06 −2.68 to 2.81 0.96
groupaFAAHb
YA cannabis users × FAAH 0.62 −1.24 to 2.47 0.51 −0.11 −3.06 to 2.84 0.94
FEP Patients × FAAH 0.75 −1.47 to 2.96 0.51 2.03 −1.49 to 5.54 0.25
Constant 13.30 10.53 to 16.07 <0.001 16.75 12.17 to 21.33 <0.001
N 590 590
Wald χ2(12) 68.62, p < 0.001 43.85 p < 0.001
aReference category: GAP controls.
bReference category: GAP controls with homozygote FAAH CC genotype; multiple comparisons are corrected with a FDR of 0.05. Results in bold are significant.
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neuroanatomically precise, genome-wide maps of gene-
expression correlations69.
Strengths and limitations
The whole sample of this study was relatively large (n=
720), allowing exploration of if and how AKT1, COMT
and FAAH interact with different participant group on
cannabis-induced psychotic-like and euphoric experi-
ences. Although the groups analyses indicated significant
differences in demographics and cannabis-related vari-
ables between the FEP, GAP controls and YA. Therefore,
the findings from the group comparisons should be
interpreted cautiously. We chose the three SNPs in
question based on a strong hypothesis-driven rationale
and best genetic coverage, to guarantee a good quality and
reliable genetic analysis. Indeed, this is why the CNR1
gene was not included as it did not have good coverage.
Limitations of this study include the behavioural genetics
approach, which utilises candidate genes that are typically
common variants, and as such only have small effects,
hampering our power to detect effects. The multi-ethnic
nature of the sample may also be considered a limitation
because COMT and FAAH variant frequencies show
differences between the minor allele frequency estimates
in African and European populations62. However, as well
as controlling for ethnicity, we conducted sensitivity
analyses, which did not significantly modify the results.
Further, we did not investigate genotype in an additive
manner but in a binary fashion in order to increase power.
It should be noted that HWE was violated for the dis-
tribution of FAAH in GAP control participants only;
however, this did not modify the overall HWE for FAAH.
We assessed baseline group differences in age, gender,
ethnicity and cannabis use variables (age of first use, fre-
quency, and years of use) but other potential confounders,
such as the type of cannabis used (THC:CBD ratio), grams
per day or whether cannabis was smoked with tobacco,
were not assessed. Recall bias may have reduced the
reliability of the CEQ and the retrospective measure of the
patterns of cannabis use. Since THC has an acutely
amnestic effect, retrospective reporting of intoxicated
experience is necessarily questionable. Retrospective
reports would be influenced by other experiences such as
the anxiogenic effects of the drug.
Conclusions
Investigating the underlying mechanisms of the poten-
tial association between cannabis and risk for psychosis is
crucial for the better understanding of the aetiology of
psychotic disorders and for the development of preven-
tion interventions. This study combined a well char-
acterised large sample of FEP cases and controls with a
naturalistic study of young adult recreational cannabis
users. We found that FEP patients experienced greater
cPLEs than GAP controls and YA cannabis users, but YA
cannabis users experienced the greatest cEEs, followed by
FEP cases and then controls. Whilst controlling for a
range of confounders, including demographics and mul-
tiple indicators of cannabis use, there was no evidence
that AKT1, COMT of FAAH influenced cannabis-
induced psychotic-like or euphoric experiences. Further,
there was no evidence for interactions between these
SNPs and group, on cannabis-induced experiences.
Future direction might focus on building genetic path-
ways scores based on eCB system relevant SNPs to further
explore its role in shaping individual susceptibility to the
psychotogenic effect of heavy cannabis use.
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